<p>丹纳赫公司（Danaher Corporation，DHR）在最近几个月经历了过山车般的波动，由于第四季度业绩低于预期以及生物科技和制药行业需求疲软，其股价遭受了重大打击。然而，分析师们现在建议该股已经下跌到足够的程度，可能是时候买入了。让我们深入了解细节，看看这是否是一个合理的投资策略。</p>
<p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png"/></p>
<p>丹纳赫最近的财务表现喜忧参半。该公司报告 2024 年第四季度净收益为 11 亿美元，或每股稀释普通股收益 1.49 美元，非 GAAP 调整后的每股稀释净收益为 2.14 美元。收入同比增长 2.0%，达到 65 亿美元，非 GAAP 核心收入增长 1.0%。尽管这些数字显示出一定的增长，但仍未达到华尔街的预期，导致股价下跌。</p>
<p>业绩未达预期的主要原因是生物科技和制药客户对药物开发所需工具和服务的需求疲软。这一趋势令人担忧，因为它表明生命科学和诊断领域可能出现放缓，而这些正是丹纳赫的核心业务。然而，考虑更广泛的背景和公司的长期前景是至关重要的。</p>
<p>丹纳赫在提供稳健的财务业绩和保持强劲的利润率方面有着良好的记录。2022 年，该公司报告第四季度净收益同比增长 25.0%，全年增长 13.5%。这一历史表现表明，丹纳赫具备在困难时期应对挑战的韧性和战略重点。</p>
<p>此外，丹纳赫强劲的现金流状况使其能够投资于增长机会，通过分红和股票回购向股东返还资本，并保持财务灵活性。该公司在 2024 年执行了 45 亿美元的股票回购，展示了其向股东回馈价值的承诺。此外，丹纳赫将季度分红提高至每股 0.32 美元，使其成为收入导向投资者的一个有吸引力的选择。</p>
<p>展望未来，丹纳赫对 2025 年第一季度和全年的展望表明，公司预计非 GAAP 核心收入将同比增长约 3%。这一积极展望表明，丹纳赫对其未来收入增长和财务健康的能力充满信心。</p>
<p>然而，考虑丹纳赫在不久的将来可能面临的潜在风险和挑战是至关重要的。市场波动、生物科技和制药行业需求疲软以及监管风险可能会影响公司的长期增长前景和股价表现。此外，丹纳赫对生命科学和诊断的依赖、收购整合以及货币波动也构成潜在风险。</p>
<p>总之，尽管丹纳赫最近的财务表现令人失望，但公司的强大基本面、稳健的现金流以及对未来增长的积极展望使其成为一个有吸引力的投资选择。分析师们建议在当前价格水平买入该股，表明市场对最近的业绩未达预期反应过度，股价已经下跌到足够的程度，呈现出买入机会。然而，投资者在做出投资决策之前应仔细考虑潜在的风险和挑战。</p>

丹纳赫

<p>丹纳赫公司的股票因第四季度业绩低于预期以及生物技术行业需求疲软而下跌。分析师建议现在可能是买入的时机，指出丹纳赫强劲的财务历史、稳健的现金流以及对 2025 年的积极展望，预计收入将增长。尽管近期表现令人失望，但公司通过回购和分红对股东价值的承诺使其成为一个有吸引力的选择。然而，潜在风险包括市场波动和行业需求挑战。投资者在决定投资之前应权衡这些因素</p>

<p>Danaher Corporation (DHR) has been on a rollercoaster ride in recent months, with its stock price taking a significant hit due to weaker-than-expected fourth-quarter earnings and soft demand in the biotech and pharmaceutical sectors. However, analysts are now suggesting that the stock has fallen far enough and that it might be time to buy. Let's dive into the details and see if this is a sound investment strategy.</p>
<div class="lb-trans"><p>丹纳赫公司（Danaher Corporation，DHR）在最近几个月经历了过山车般的波动，由于第四季度业绩低于预期以及生物科技和制药行业需求疲软，其股价遭受了重大打击。然而，分析师们现在建议该股已经下跌到足够的程度，可能是时候买入了。让我们深入了解细节，看看这是否是一个合理的投资策略。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png" alt="" original-src="https://lh-prod-oper-pub-opercenter.s3.amazonaws.com/discovery-image/compress-1a621c912f820002.png"/></p>
<p>Danaher's recent financial performance has been a mixed bag. The company reported net earnings of $1.1 billion, or $1.49 per diluted common share, for the fourth quarter of 2024, with non-GAAP adjusted diluted net earnings per common share at $2.14. Revenues increased by 2.0% year-over-year to $6.5 billion, and non-GAAP core revenue increased by 1.0%. While these numbers show some growth, they fell short of Wall Street's expectations, leading to a decline in the stock price.</p>
<div class="lb-trans"><p>丹纳赫最近的财务表现喜忧参半。该公司报告 2024 年第四季度净收益为 11 亿美元，或每股稀释普通股收益 1.49 美元，非 GAAP 调整后的每股稀释净收益为 2.14 美元。收入同比增长 2.0%，达到 65 亿美元，非 GAAP 核心收入增长 1.0%。尽管这些数字显示出一定的增长，但仍未达到华尔街的预期，导致股价下跌。</p>
</div><p>The primary reason for the earnings miss was soft demand for tools and services used in drug development by biotech and pharmaceutical clients. This trend is concerning, as it indicates a potential slowdown in the life sciences and diagnostics sectors, which are Danaher's core businesses. However, it's essential to consider the broader context and the company's long-term prospects.</p>
<div class="lb-trans"><p>业绩未达预期的主要原因是生物科技和制药客户对药物开发所需工具和服务的需求疲软。这一趋势令人担忧，因为它表明生命科学和诊断领域可能出现放缓，而这些正是丹纳赫的核心业务。然而，考虑更广泛的背景和公司的长期前景是至关重要的。</p>
</div><p>Danaher has a strong track record of delivering solid financial results and maintaining robust profit margins. In 2022, the company reported a 25.0% year-over-year increase in net earnings for the fourth quarter and a 13.5% year-over-year increase for the full year. This historical performance suggests that danaher has the resilience and strategic focus to navigate through challenging times.</p>
<div class="lb-trans"><p>丹纳赫在提供稳健的财务业绩和保持强劲的利润率方面有着良好的记录。2022 年，该公司报告第四季度净收益同比增长 25.0%，全年增长 13.5%。这一历史表现表明，丹纳赫具备在困难时期应对挑战的韧性和战略重点。</p>
</div><p>Moreover, Danaher's strong cash flow position allows it to invest in growth opportunities, return capital to shareholders through dividends and share buybacks, and maintain financial flexibility. The company executed a $4.5 billion share buyback in 2024, demonstrating its commitment to returning value to shareholders. Additionally, Danaher increased its quarterly dividend to $0.32 per share, making it an attractive option for income-focused investors.</p>
<div class="lb-trans"><p>此外，丹纳赫强劲的现金流状况使其能够投资于增长机会，通过分红和股票回购向股东返还资本，并保持财务灵活性。该公司在 2024 年执行了 45 亿美元的股票回购，展示了其向股东回馈价值的承诺。此外，丹纳赫将季度分红提高至每股 0.32 美元，使其成为收入导向投资者的一个有吸引力的选择。</p>
</div><p>Looking ahead, Danaher's outlook for the first quarter and full year 2025 indicates that the company expects non-GAAP core revenue to increase by approximately 3% year-over-year. This positive outlook suggests that Danaher is confident in its ability to grow its revenue and maintain its financial health in the future.</p>
<div class="lb-trans"><p>展望未来，丹纳赫对 2025 年第一季度和全年的展望表明，公司预计非 GAAP 核心收入将同比增长约 3%。这一积极展望表明，丹纳赫对其未来收入增长和财务健康的能力充满信心。</p>
</div><p>However, it's essential to consider the potential risks and challenges that Danaher may face in the near future. Market volatility, soft demand in the biotech and pharmaceutical sectors, and regulatory risks could impact the company's long-term growth prospects and stock performance. Additionally, Danaher's dependency on life sciences and diagnostics, integration of acquisitions, and currency fluctuations pose potential risks.</p>
<div class="lb-trans"><p>然而，考虑丹纳赫在不久的将来可能面临的潜在风险和挑战是至关重要的。市场波动、生物科技和制药行业需求疲软以及监管风险可能会影响公司的长期增长前景和股价表现。此外，丹纳赫对生命科学和诊断的依赖、收购整合以及货币波动也构成潜在风险。</p>
</div><p>In conclusion, while Danaher's recent financial performance has been disappointing, the company's strong fundamentals, robust cash flow, and positive outlook for future growth make it an attractive investment option. Analysts' recommendations to buy the stock at its current price level suggest that the market has overreacted to the recent earnings miss, and the stock has fallen far enough to present a buying opportunity. However, investors should carefully consider the potential risks and challenges before making an investment decision.</p>
<div class="lb-trans"><p>总之，尽管丹纳赫最近的财务表现令人失望，但公司的强大基本面、稳健的现金流以及对未来增长的积极展望使其成为一个有吸引力的投资选择。分析师们建议在当前价格水平买入该股，表明市场对最近的业绩未达预期反应过度，股价已经下跌到足够的程度，呈现出买入机会。然而，投资者在做出投资决策之前应仔细考虑潜在的风险和挑战。</p>
</div>

丹纳赫股票已经跌得够多了。分析师建议现在买入